Modifications épigénétiques et instabilité génomique dans les cellules B normales et tumorales

Bases moléculaires de pathologies humaines

Les plasmocytes sont des cellules effectrices critiques et les sentinelles à longue durée de vie de la mémoire immunitaire.
La maturation des cellules B doit être finement régulée pour assurer une réponse immunitaire efficace. Sur le plan transcriptionnel, la différenciation des cellules B en plasmocytes est associée à des remaniements coordonnés des profils d’expression géniques qui vont réprimer les gènes B et activer le programme d’expression plasmocytaire.
Ces modifications sont guidées par des facteurs de transcription B et plasmocytaires qui présentent des boucles de rétro-contrôle entre eux. Bien que le rôle complexe des facteurs de transcription impliqués dans la différenciation plasmocytaire ait été analysé, les mécanismes contrôlant ces remaniements transcriptionnels restent mal connus.
Nous recherchons à caractériser et comprendre les modifications épigénétiques, structurales, architecturales et le remodelage de la chromatine au cours de la différenciation plasmocytaire.
Nous nous attardons à identifier les voies impliquées dans ce remodelage de la chromatine et les impacts transcriptionnels sous-jacents. Nous recherchons aussi à comprendre les mécanismes oncogéniques au cours de la différenciation plasmocytaire pouvant conduire à l’émergence de néoplasies B matures.

Les hémopathies malignes des cellules B matures sont des cancers génétiquement et cliniquement hétérogènes. L'amélioration des traitements proviendra d'une meilleure caractérisation moléculaire pour développer des approches de médecine de précision prenant en compte l'hétérogénéité et l'évolution sous-clonale.
Notre laboratoire utilise les données de génomique, la bioinformatique et des modèles cellulaires uniques pour étudier les cellules B matures et les plasmocytes en nous focalisant sur les modifications épigénétiques et l'instabilité génomique. Ceci nous permet d’étudier la tumorigénèse, comprendre les mécanismes de progression et de résistance pour développer de nouveaux outils diagnostiques et thérapeutiques.

Ces travaux sont menés en lien avec d’autres équipes de l’IGH et les départements d’hématologie biologique et clinique du CHU de Montpellier.
A travers ces collaborations et nos implications au sein du laboratoire suivi des thérapies innovantes du CHU de Montpellier, dédié au diagnostic et suivi de la maladie résiduelle des patients atteints de néoplasies plasmocytaires, nous cherchons à accélérer le transfert des résultats issus de recherches fondamentales vers la clinique.

Nous avons également créé une société privée Diag2Tec pour valoriser les travaux de l’équipe.

Caroline BRET
Chercheur

NULL
Hugues DE BOUSSAC
Chercheur

0467337903
Charles HERBAUX
Chercheur

0467330490
Malik LUTZMANN
Chercheur

NULL
Jerome MOREAUX
Chercheur

0467337903
Morgane Thomas
Morgane THOMAS
Chercheur

0467337903
Laure DUTRIEUX
Doctorant

0467335708
Matthieu ABOULADZE
RESPONSABLE TECHNIQUE DE LA COLLECTION HEMODIAG CRB
ITA

0467335706
Laura Alibert
Laura ALIBERT
ITA

0467337903
Matthieu Angles
Matthieu ANGLES
ITA

0411759728
Audrey Bost
Audrey BOST
ITA

0434359932
Elvira GARCIA DE PACO
ITA

0467335706
Lauryn Jaffory
Lauryn JAFFORY
ITA

0467335708
Ouissem KARMOUS-GADACHA
ITA

0467335706
Sara OVEJERO MERINO
ITA

0467335708
Guilhem REQUIRAND
ITA

0467335707
Nicolas ROBERT
ITA

0467330490
Andrea Romero
Andrea ROMERO
ITA

046733xxxx
Dassou SIKA
Ingénieur en développement et déploiement d'applications
ITA

0467337903
Miss Leriem Zellagui
Miss Leriem ZELLAGUI
ITA

0467337903

Publications de l'équipe

KDM6A controls immunogenicity in MM.

Moreaux J

Single-hit genome editing optimized for maturation in B cells redirects their specificity toward tumor antigens.

Ueda N, Cahen M, Leonard J, Deleurme L, Dreano S, Sirac C, Galy A, Moreaux J, Danger Y, Cogné M

CD38, CD39, and BCL2 differentiate disseminated forms of high-grade B-cell lymphomas in biological fluids from Burkitt lymphoma and diffuse large B-cell lymphoma.

Marianini P, Lacheretz-Szablewski V, Almeras M, Moreaux J, Bret C

BHLHE41, a transcriptional repressor involved in physiological processes and tumor development.

Bret C, Desmots-Loyer F, Moreaux J, Fest T

A case of refractory IgG4-related disease successfully treated with daratumumab and lenalidomide.

Coulomb D, Szablewski V, Robert N, Dupuy AM, Berrahouane R, Goulabchand R, Moreaux J, Maria ATJ, Herbaux C

FCGR3A F158V alleles frequency differs in multiple myeloma patients from healthy population.

Constantinides M, Robert N, Multrier C, Coënon L, Campos-Mora M, Jacquard C, Gao F, Zemiti S, Presumey J, Cartron G, Moreaux J, Villalba M

Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation.

Hummel M, Hielscher T, Emde-Rajaratnam M, Salwender H, Beck S, Scheid C, Bertsch U, Goldschmidt H, Jauch A, Moreaux J, Seckinger A, Hose D

Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry.

Herbaux C, Bret C, Bachy E, Bories P, Di Blasi R, Cuffel A, Gastinne T, Lamy T, Roussel M, Bouabdallah K, Beauvais D, Cartron G, Bay JO, Blaise D, Rubio MT, Mohty M, Le Bras F, Casasnovas O, Guy J, Guidez S, Llorente CC, Hermine O, La Rochelle LD, Carras S, Guffroy B, Caillat-Zucman S, Houot R, Le Gouill S

Flow cytometric analysis of peripheral blood neutrophil myeloperoxidase expression in myelodysplastic neoplasms (MPO-MDS-Valid): protocol for a multicentre diagnostic accuracy study.

Planta C, Bret C, Manzoni D, Lhoumeau AC, Mayeur Rousse C, Ticchioni M, Campos L, Eischen A, Gonnet N, Merle R, Seigneurin A, Paul F, Comte E, Allieri-Rosenthal A, Tondeur S, Regnart C, Jacob MC, Labarère J, Park S, Raskovalova T

Integrative single-cell chromatin and transcriptome analysis of human plasma cell differentiation.

Alaterre E, Ovejero S, Bret C, Dutrieux L, Sika D, Fernandez Perez R, Espéli M, Fest T, Cogné M, Martín-Subero JI, Milpied P, Cavalli G, Moreaux J

Long-term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO).

Laribi K, Poulain S, Willems L, Merabet F, Herbaux C, Roos-Weil D, Laribi de Materre I, Roussel X, Nudel M, Tricot S, Dupuis J, Le Calloch R, Bareau B, Leblond V

An atlas of cells in the human tonsil.

Massoni-Badosa R, Aguilar-Fernández S, Nieto JC, Soler-Vila P, Elosua-Bayes M, Marchese D, Kulis M, Vilas-Zornoza A, Bühler MM, Rashmi S, Alsinet C, Caratù G, Moutinho C, Ruiz S, Lorden P, Lunazzi G, Colomer D, Frigola G, Blevins W, Romero-Rivero L, Jiménez-Martínez V, Vidal A, Mateos-Jaimez J, Maiques-Diaz A, Ovejero S, Moreaux J, Palomino S, Gomez-Cabrero D, Agirre X, Weniger MA, King HW, Garner LC, Marini F, Cervera-Paz FJ, Baptista PM, Vilaseca I, Rosales C, Ruiz-Gaspà S, Talks B, Sidhpura K, Pascual-Reguant A, Hauser AE, Haniffa M, Prosper F, Küppers R, Gut IG, Campo E, Martin-Subero JI, Heyn H

en savoir plus

Combined inhibition of Wee1 and Chk1 as a therapeutic strategy in multiple myeloma.

Bruyer A, Dutrieux L, de Boussac H, Martin T, Chemlal D, Robert N, Requirand G, Cartron G, Vincent L, Herbaux C, Lutzmann M, Bret C, Pasero P, Moreaux J, Ovejero S

+ Maintien de l'intégrité du génome au cours de la réplication

Immunophenotypic portrait of leukemia-associated-phenotype markers in B acute lymphoblastic leukemia.

Boris E, Theron A, Montagnon V, Rouquier N, Almeras M, Moreaux J, Bret C

RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma.

Emde-Rajaratnam M, Beck S, Benes V, Salwender H, Bertsch U, Scheid C, Hänel M, Weisel K, Hielscher T, Raab MS, Goldschmidt H, Jauch A, Maes K, De Bruyne E, Menu E, De Veirman K, Moreaux J, Vanderkerken K, Seckinger A, Hose D

Extreme thrombocytosis with an aggressive evolution harboring a novel variant of calreticulin (CALR) in exon 3.

Bonnet S, Carillo S, Legrand B, Burroni B, Lavabre-Bertrand T, Requirand G, Robert N, Fornero L, Al Mansoori A, Moreaux J, Cartron G, Gabellier L, Herbaux C

Non-Relapse Mortality after CAR T-Cell therapy for Large B-Cell Lymphoma: A LYSA Study from the DESCAR-T Registry.

Lemoine J, Bachy E, Cartron G, Beauvais D, Gastinne T, Di Blasi R, Rubio MT, Guidez S, Mohty M, Casasnovas O, Joris M, Castilla-Llorente C, Haioun C, Hermine O, Loschi M, Carras S, Bories P, Fradon T, Herbaux C, Sesques P, Le Gouill S, Morschhauser F, Thieblemont C, Houot R

EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma.

Chemlal D, Varlet E, Machura A, Ovejero S, Requirand G, Robert N, Cartron G, Alaterre E, Bret C, Vincent L, Herbaux C, Cavalli G, Bruyer A, De Boussac H, Moreaux J

en savoir plus

S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability in multiple myeloma.

Wang Y, Muylaert C, Wyns A, Vlummens P, De Veirman K, Vanderkerken K, Zaal E, Berkers C, Moreaux J, De Bruyne E, Menu E

en savoir plus

Var∣Decrypt: a novel and user-friendly tool to explore and prioritize variants in whole-exome sequencing data.

Salma M, Alaterre E, Moreaux J, Soler E

en savoir plus

Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA.

Marouf A, Molinari N, Sibon D, Cottereau AS, Kanoun S, Antoine C, Debureaux PE, Cavalieri D, Fornecker LM, Casasnovas RO, Herbaux C, Amorim S, Rossi C, Bouscary D, Brice P, Ghesquieres H, Tamburini J, Deau B

3-O sulfation of syndecan-1 mediated by the sulfotransferase HS3ST3a1 enhances myeloma aggressiveness.

Baert L, Manfroi B, Quintero M, Chavarria O, Barbon PV, Clement E, Zeller A, Van Kuppevelt T, Sturm N, Moreaux J, Tveita A, Bogen B, McKee T, Huard B

en savoir plus

Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group.

Al Tabaa Y, Casasnovas RO, Baillet C, Bachy E, Nicolas-Virelizier E, Schiano De Colella JM, Bailly C, Kanoun S, Guidez S, Gyan E, Gressin R, Morineau N, Ysebaert L, Le Gouill S, Tilly H, Houot R, Morschhauser F, Cartron G, Herbaux C

Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study.

Cartron G, Bachy E, Tilly H, Daguindau N, Pica GM, Bijou F, Mounier C, Clavert A, Damaj GL, Slama B, Casasnovas O, Houot R, Bouabdallah K, Sibon D, Fitoussi O, Morineau N, Herbaux C, Gastinne T, Fornecker LM, Haioun C, Launay V, Araujo C, Benbrahim O, Sanhes L, Gressin R, Gonzalez H, Morschhauser F, Ternant D, Xerri L, Tarte K, Pranger D

Anti-PD-1 therapy can possibly reverse CAR T cells exhaustion in DLBCL.

Lamure S, Herbaux C

Editorial: Transcriptional control in normal and malignant B-lymphocytes.

Jerome Moreaux, Alexander A Shtil

Preventive plasmapheresis for rituximab related flare in cryoglobulinemic vasculitis.

Fornero L, Kanouni T, Tudesq JJ, Pochard C, Verot P, Renier W, Gabellier L, Cartron G, Guilpain P, Herbaux C

Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia.

Buske C, Tedeschi A, Trotman J, García-Sanz R, MacDonald D, Leblond V, Mahe B, Herbaux C, Matous JV, Tam CS, Heffner LT, Varettoni M, Palomba ML, Shustik C, Kastritis E, Treon SP, Ping J, Hauns B, Arango-Hisijara I, Dimopoulos MA

The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance.

Ovejero S, Viziteu E, Dutrieux L, Devin J, Lin YL, Alaterre E, Jourdan M, Basbous J, Requirand G, Robert N, de Boussac H, Seckinger A, Hose D, Vincent L, Herbaux C, Constantinou A, Pasero P, Moreaux J

+ Instabilité Génétique et Cancer / Maintien de l'intégrité du génome au cours de la réplication

en savoir plus

LAIR1, an ITIM-Containing Receptor Involved in Immune Disorders and in Hematological Neoplasms.

Van Laethem F, Donaty L, Tchernonog E, Lacheretz-Szablewski V, Russello J, Buthiau D, Almeras M, Moreaux J, Bret C

en savoir plus

Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA.

Damaj G, Aubrais R, Bouabdallah K, Chartier L, Herbaux C, Banos A, Brice P, Sibon D, Schiano JM, Cluzeau T, Laribi K, LE Calloch R, Bellal M, Delapierre B, Daguindau N, Amorim S, Agbetiafa K, Chauchet A, Besson C, Durot E, Bonnet C, Fouillet L, Bijou F, Tournilhac O, Gaulard P, Parrens MC

Targeting the β(2) -adrenergic receptor increases chemosensitivity in multiple myeloma by induction of apoptosis and modulating cancer cell metabolism.

Satilmis H, Verheye E, Vlummens P, Oudaert I, Vandewalle N, Fan R, Knight JM, De Beule N, Ates G, Massie A, Moreaux J, Maes A, De Bruyne E, Vanderkerken K, Menu E, Sloan EK, De Veirman K

miRNA profile at diagnosis predicts treatment outcome in patients with B-chronic lymphocytic leukemia: A FILO study

Isabelle Duroux-Richard, Anne-Laure Gagez, Elina Alaterre, Rémi Letestu, Olfa Khalifa, Christian Jorgensen, Stéphane Leprêtre, Emmanuelle Tchernonog, Jérôme Moreaux, Guillaume Cartron, Florence Apparailly

Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B-cell lymphoma.

Daniel A, Ghez D, Ravaiau C, Cavalieri D, Tournilhac O, Herbaux C, Roriz M, Wemeau M, Guillet S, Bossard JB, Hélène D, Kaphan E, Caroline R, Florence L, Pierache A, Michel M, Godeau B, Terriou L

Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach.

Vlummens P, Verhulst S, De Veirman K, Maes A, Menu E, Moreaux J, De Boussac H, Robert N, De Bruyne E, Hose D, Offner F, Vanderkerken K, Maes K

Therapy-related Myeloid Neoplasms in Patients With Chronic Lymphocytic Leukemia Who Received FCR/FC as Frontline Therapy.

Laribi K, Baugier de Materre A, Ghez D, Dartigeas C, Tomowiak C, Mahé B, Micol JB, Merabet F, Leprêtre S, Herbaux C, Ysebaert L, Le Calloch R, Willems L, Voldoire M, Roos-Weil D, Bravetti C, Touileb Y, Davi F, Nguyen-Khac F, Maloum K, Béné MC

Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5-year analysis of the French early access program (EPA).

Manson G, Herbaux C, Schiano JM, Casasnovas O, Stamatoullas A, Deau B, Schmitt A, Regny C, Bouabdallah K, Chauchet A, Ghesquieres H, Tempescul A, Dulery R, Nicolas-Virelizier E, Delmer A, Borel C, Dercle L, Brice P, Houot R, Lymphoma Study Association (LYSA)

The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of acute myeloid leukemias.

Paolillo R, Boulanger M, Gâtel P, Gabellier L, De Toledo M, Tempé D, Hallal R, Akl D, Moreaux J, Baik H, Gueret E, Recher C, Sarry JE, Cartron G, Piechaczyk M, Bossis G

PIM2 kinase has a pivotal role in plasmablast generation and plasma cell survival, opening up novel treatment options in myeloma.

Haas M, Caron G, Chatonnet F, Manenti S, Alaterre E, Devin J, Delaloy C, Bertolin G, Viel R, Pignarre A, Llamas-Gutierrez F, Marchalot A, Decaux O, Tarte K, Delpy L, Moreaux J, Fest T

Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell Lymphoma.

Devin J, Caneque T, Lin YL, Mondoulet L, Veyrune JL, Abouladze M, Garcia De Paco E, Karmous Gadacha O, Cartron G, Pasero P, Bret C, Rodriguez R, Moreaux J

en savoir plus

Angiogenic factors could help us to define patients obtaining complete response with undetectable minimal residual disease in untreated CLL patients treated by FCR: results from the CLL2010FMP, a FILO study.

Gagez AL, Paul F, Alaterre E, Gouilleux-Gruart V, Tuaillon E, Lepretre S, Ternant D, Letestu R, Moreaux J, Cartron G

RNA-Sequencing-Based Transcriptomic Score with Prognostic and Theranostic Values in Multiple Myeloma.

Alaterre E, Vikova V, Kassambara A, Bruyer A, Robert N, Requirand G, Bret C, Herbaux C, Vincent L, Cartron G, Elemento O, Moreaux J

Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.

Buske C, Tedeschi A, Trotman J, García-Sanz R, MacDonald D, Leblond V, Mahe B, Herbaux C, Matous JV, Tam CS, Heffner LT, Varettoni M, Palomba ML, Shustik C, Kastritis E, Treon SP, Ping J, Hauns B, Arango-Hisijara I, Dimopoulos MA

Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma.

Herviou L, Ovejero S, Izard F, Karmous-Gadacha O, Gourzones C, Bellanger C, De Smedt E, Ma A, Vincent L, Cartron G, Jin J, De Bruyne E, Grimaud C, Julien E, Moreaux J

The microenvironment of DLBCL is characterized by noncanonical macrophages recruited by tumor-derived CCL5.

Manfroi B, De Grandis M, Moreaux J, Tabruyn S, Mayol JF, Quintero M, Righini C, Sturm N, Aurrand-Lions M, Huard B

Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy.

Lamure S, Van Laethem F, De Verbizier D, Lozano C, Gehlkopf E, Tudesq JJ, Serrand C, Benzaoui M, Kanouni T, Quintard A, De Vos J, Tchernonog E, Platon L, Ayrignac X, Ceballos P, Sirvent A, François M, Guedon H, Quittet P, Mongellaz C, Conte A, Herbaux C, Bret C, Taylor N, Dardalhon V, Cartron G

Transcription/Replication Conflicts in Tumorigenesis and Their Potential Role as Novel Therapeutic Targets in Multiple Myeloma.

Dutrieux L, Lin YL, Lutzmann M, Rodriguez R, Cogné M, Pasero P, Moreaux J

Discovery of candidate DNA methylation cancer driver genes.

Pan H, Renaud L, Chaligne R, Bloehdorn J, Tausch E, Mertens D, Fink AM, Fischer K, Zhang C, Betel D, Gnirke A, Imielinski M, Moreaux J, Hallek M, Meissner A, Stilgenbauer S, Wu CJ, Elemento O, Landau DA

en savoir plus

Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia.

Tomowiak C, Poulain S, Herbaux C, Perrot A, Mahé B, Morel P, Aurran T, Tournilhac O, Leprêtre S, Assaad S, Villemagne B, Casasnovas O, Nollet D, Roos-Weil D, Chevret S, Leblond V

G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor-mediated cell death.

De Smedt E, Devin J, Muylaert C, Robert N, Requirand G, Vlummens P, Vincent L, Cartron G, Maes K, Moreaux J, De Bruyne E

RNA-sequencing data-driven dissection of human plasma cell differentiation reveals new potential transcription regulators.

Kassambara A, Herviou L, Ovejero S, Jourdan M, Thibaut C, Vikova V, Pasero P, Elemento O, Moreaux J

en savoir plus

Immunotherapy perspectives in the new era of B-cell editing.

Ueda N, Cahen M, Danger Y, Moreaux J, Sirac C, Cogné M

Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma

Sara Ovejero, Jerome Moreaux

lire la publication

en savoir plus

Role of Polycomb Complexes in Normal and Malignant Plasma Cells.

Varlet E, Ovejero S, Martinez AM, Cavalli G, Moreaux J

DNA Repair Expression Profiling to Identify High-Risk Cytogenetically Normal Acute Myeloid Leukemia and Define New Therapeutic Targets

Ludovic Gabellier, Caroline Bret, Guillaume Bossis, Guillaume Cartron, Jérôme Moreaux

lire la publication

A Retrospective Comparison of DLI and gDLI for Post-Transplant Treatment.

Lamure S, Paul F, Gagez AL, Delage J, Vincent L, Fegueux N, Sirvent A, Gehlkopf E, Veyrune JL, Yang LZ, Kanouni T, Cacheux V, Moreaux J, Bonafoux B, Cartron G, De Vos J, Ceballos P

Characterization of immortalized human islet stromal cells reveals a MSC-like profile with pancreatic features.

Villard O, Armanet M, Couderc G, Bony C, Moreaux J, Noel D, De Vos J, Klein B, Veyrune JL, Wojtusciszyn A

Kinome expression profiling to target new therapeutic avenues in multiple myeloma

Hugues de Boussac, Angélique Bruyer, Michel Jourdan, Anke Maes, Nicolas Robert, Claire Gourzones, Laure Vincent, Anja Seckinger, Guillaume Cartron, Dirk Hose, Elke De Bruyne, Alboukadel Kassambara, Philippe Pasero, Jérôme Moreaux

lire la publication

en savoir plus

[CD38 antibodies in multiple myeloma].

Moreaux J

CD38 antibodies in multiple myeloma

Jérôme Moreaux

lire la publication

Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma.

Maes A, Maes K, Vlummens P, De Raeve H, Devin J, Szablewski V, De Veirman K, Menu E, Moreaux J, Vanderkerken K, De Bruyne E

Treatment may be harmful : mechanisms/preduction/prevention of drug-induced DNA damage and repair in multiple myeloma

Claire Gourzones, Caroline Bret, Jerome Moreaux

lire la publication

Phenotypic Characterization of Diffuse Large B-Cell Lymphoma Cells and Prognostic Impact.

Devin J, Kassambara A, Bruyer A, Moreaux J, Bret C

Phenotype Characterization of Diffuse Large B cell Lymphoma Cells and Prognostic Impact

Julie Devin, Alboukadel Kassambara, Angélique Bruyer, Jérôme Moreaux and Caroline Bret

lire la publication

Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial.

Hose D, Beck S, Salwender H, Emde M, Bertsch U, Kunz C, Scheid C, Hänel M, Weisel K, Hielscher T, Raab MS, Goldschmidt H, Jauch A, Moreaux J, Seckinger A

The hydroxymethylome of multiple myeloma identifies FAM72D as a 1q21 marker linked to proliferation.

Chatonnet F, Pignarre A, Sérandour AA, Caron G, Avner S, Robert N, Kassambara A, Laurent A, Bizot M, Agirre X, Prosper F, Martin-Subero JI, Moreaux J, Fest T, Salbert G

The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma.

Maes A, Maes K, De Raeve H, De Smedt E, Vlummens P, Szablewski V, Devin J, Faict S, De Veirman K, Menu E, Offner F, Spaargaren M, Moreaux J, Vanderkerken K, Van Valckenborgh E, De Bruyne E

Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells

Claire Gourzones, Céline Bellanger, Sylvain Lamure, Ouissem Karmous Gadacha, Elvira Garcia De Paco, Laure Vincent, Guillaume Cartron, Bernard Klein and Jérôme Moreau

lire la publication

EZH2 is overexpressed in transitional preplasmablasts and is involved in human plasma cell differentiation

Laurie Herviou, Michel Jourdan, Anne-Marie Martinez, Giacomo Cavalli, Jerome Moreaux

lire la publication

en savoir plus

Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance

Veronika Vikova, Michel Jourdan, Nicolas Robert, Guilhem Requirand, Stéphanie Boireau, Angélique Bruyer, Laure Vincent, Guillaume Cartron, Bernard Klein, Olivier Elemento, Alboukadel Kassambara, Jérôme Moreaux

lire la publication

BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myeloma.

Requirand G, Robert N, Boireau S, Vincent L, Seckinger A, Bouhya S, Ceballos P, Cartron G, Hose D, Klein B, Moreaux J

PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs

Laurie Herviou, Alboukadel Kassambara, Stéphanie Boireau, Nicolas Robert, Guilhem Requirand, Carsten Müller-Tidow, Laure Vincent, Anja Seckinger, Hartmut Goldschmidt, Guillaume Cartron, Dirk Hose, Giacomo Cavalli & Jerome Moreaux

lire la publication

en savoir plus

Tumor-associated neutrophils correlate with poor prognosis in diffuse large B-cell lymphoma patients.

Manfroi B, Moreaux J, Righini C, Ghiringhelli F, Sturm N, Huard B

Analysis of Global Gene Expression Profiles.

Kassambara A, Moreaux J

An epigenetic regulator-related score (EpiScore) predicts survival in patients with diffuse large B cell lymphoma and identifies patients who may benefit from epigenetic therapy

Vanessa Szablewski, Caroline Bret, Alboukadel Kassambara, Julie Devin, Guillaume Cartron, Valérie Costes-Martineau and Jérôme Moreaux

lire la publication

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells

Angelique Bruyer, Ken Maes, Laurie Herviou, Alboukadel Kassambara, Anja Seckinger, Guillaume Cartron, Thierry Rème, Nicolas Robert, Guilhem Requirand, Stéphanie Boireau, Carsten Müller-Tidow, Jean-luc Veyrune, Laure Vincent, Salahedine Bouhya, Hartmut Goldschmidt, Karin Vanderkerken, Dirk Hose, Bernard Klein, Elke De Bruyne & Jerome Moreaux

lire la publication

en savoir plus

Combined inhibition of two bad prognosis genes: Chk1 and Wee1 as a new therapeutic strategy for Multiple Myeloma [Poster]

Angélique Bruyer, Hugues de Boussac, Thibaut Martin, Alboukadel Kassambara, Nicolas Robert, Hose D, Anja Seckinger, Philippe Pasero, Jérôme Moreaux

lire la publication

Combined inhibition of two bad prognosis genes: Chk1 and Wee1 as a new therapeutic strategy for Multiple Myeloma [Abstract]

Angélique Bruyer, Hugues de Boussac, Thibaut Martin, Alboukadel Kassambara, Nicolas Robert, Hose D, Anja Seckinger, Philippe Pasero, Jérôme Moreaux

lire la publication

CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma

Elina Alaterre, Sebastien Raimbault, Hartmut Goldschmidt, Salahedine Bouhya, Guilhem Requirand, Nicolas Robert, Stéphanie Boireau, Anja Seckinger, Dirk Hose, Bernard Klein and Jérôme Moreaux

lire la publication

Automated and Simplified Identification of Normal and Abnormal Plasma Cells in Multiple Myeloma by Flow Cytometry

Elina Alaterre, Sebastien Raimbault, Jean-Michel Garcia,Thierry Reme,Guilhem Requirand, Bernard Klein, and Jerome Moreaux

lire la publication

en savoir plus

Hypoxia favors the generation of human plasma cells

Michel Jourdan, Angélique Bruyer, Alboukadel Kassambara, Bernard Klein & Jérôme Moreaux

lire la publication

en savoir plus

Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell

Alboukadel Kassambara, Michel Jourdan, Angelique Bruyer, Nicolas Robert, Veronique Pantesco, Olivier Elemento, Bernard Klein and Jerome Moreaux

lire la publication

RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma

E Viziteu, B Klein, J Basbous, Y-L Lin, C Hirtz, C Gourzones, L Tiers, A Bruyer, L Vincent, C Grandmougin, A Seckinger, H Goldschmidt, A Constantinou, P Pasero, D Hose, J Moreaux

lire la publication

en savoir plus

Differential effects of lenalidomide during plasma cell differentiation

Michel Jourdan, Maïlys Cren, Peter Schafer, Nicolas Robert, Christophe Duperray, Laure Vincent, Patrice Ceballos, Guillaume Cartron, Jean-François Rossi, Jérôme Moreaux, Rajesh Chopra, Bernard Klein

lire la publication

Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy

Caroline Bret, Elena Viziteu, Alboukadel Kassambara & Jerome Moreaux

lire la publication

en savoir plus

Chetomin, targeting HIF-1a/p300 complex, exhibits antitumour activity in multiple myeloma

Elena Viziteu, Camille Grandmougin, Hartmut Goldschmidt, Anja Seckinger, Dirk Hose, Bernard Klein, Jerome Moreaux

lire la publication

en savoir plus

DNA repair in diffuse large B-cell lymphoma: a molecular portrait

Caroline Bret, Bernard Klein, Guillaume Cartron, Jean-François Schved, Angelos Constantinou, Philippe Pasero, Jérôme Moreaux

lire la publication

en savoir plus

EZH2 in normal hematopoiesis and hematological malignancies

Laurie Herviou, Giacomo Cavalli, Guillaume Cartron, Bernard Klein and Jérôme Moreaux

lire la publication

GenomicScape : AnEasy-to-Use Web Tool for Gene Expression Data Analysis. Application to Investigate the Molecular Events in the Differentiation of B Cells into Plasma Cells

Alboukadel Kassambara, Thierry Rème, Michel Jourdan, Thierry Fest, Dirk Hose, Karin Tarte, Bernard Klein

lire la publication

Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors

J Moreaux, T Reme, W Leonard, J-L Veyrune, G Requirand, H Goldschmidt, D Hose & B Klein

lire la publication

Nucleotide excision DNA repair pathway as a therapeutic target in patients with high-risk diffuse large B cell lymphoma

Caroline Bret, Bernard Klein and Jérôme Moreaux

lire la publication

Nucleotide excision DNA repair pathway as a therapeutic target in patients with high-risk diffuse large B cell lymphoma

Caroline Bret, Bernard Klein and Jérôme Moreaux

lire la publication

Gene expression-based risk score in diffuse large B-cell lymphoma

Caroline Bret, Bernard Klein, and Jérôme Moreaux

lire la publication

Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients

Elias Bou Samra, Bernard Klein, Thérèse Commes, and Jérôme Moreaux

lire la publication

Development of gene expression based score to predict sensitivity of multiple myeloma cells to DNA methylation

Jérôme Moreaux, Thierry Rème, Wim Leonard, et al.

lire la publication

Characterization of a Transitional Preplasmablast Population in the Process of Human B Cell to Plasma Cell Differentiation

Michel Jourdan, Anouk Caraux, Gersende Caron, Nicolas Robert, Geneviève Fiol, Thierry Rème, Karine Bolloré, Jean-Pierre Vendrell, Simon Le Gallou, Frédéric Mourcin, John De Vos, Alboukadel Kassambara, Christophe Duperray, Dirk Hose, Thierry Fest, Karin Tarte and Bernard Klein

lire la publication

en savoir plus

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.

Moreaux J, Klein B, Bataille R, Descamps G, Maïga S, Hose D, Goldschmidt H, Jauch A, Rème T, Jourdan M, Amiot M, Pellat-Deceunynck C

lire la publication

en savoir plus

An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization.

Jourdan M, Caraux A, De Vos J, Fiol G, Larroque M, Cognot C, Bret C, Duperray C, Hose D, Klein B

lire la publication

en savoir plus

Thèses et hdr

Analyses génomiques et épigénomiques pour le développement d’une médecine de précision dans le myélome multiple 08/10/2019

Etude de l'implication de mécanismes épigénétiques dans la physiopathologie du myélome multiple et dans la différenciation plasmocytaire normale 13/09/2018

Identification fine des cellules plasmocytaires normales et tumorales dans la moelle osseuse de patients atteints de myélome multiple en cytométrie en flux 03/05/2017

RECQ1 Helicase Involvement in the Resistance to Replication Stress and Chemotherapy in Multiple Myeloma Myélome Multiple 24/11/2015